JOMPAC

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

EndNote Style
Index
Case Report
A case with neuropathy due to colistin after using first dose of colistin
Colistin is an antibiotic commonly used in the treatment of infection due to multiple drug resistant Gram-negative bacilli. Colistin side effects include of nephropathy and neuropathy. Neurotoxicity due to colistin can be occur as paresthesia, dizziness, visual changes, and neuromuscular blockade with ataxia. In this article, a case of 68-year-old female patient with a diagnosis of urinary tract infection due to resistant Klebsiella pneumoniae and treatment of imipenem and colistin after the first dose of colistin and her treatment colistin was stoped upon the development of paresthesia in the lips and fingers. After discontinuation of the drug, the patient’s paresthesia improved, and the treatment was continued with a combination of imipenem and trimethoprim-sulfamethoxazole. As a result, patients receiving colistin therapy should be closely monitored for symptoms of neuropathy and drug therapy should be discontinued if neurotoxicity develops.


1. Nørgaard SM, Jensen CS, Aalestrup J, Vandenbroucke-Grauls CMJE, de Boer MGJ, Pedersen AB. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review. Antimicrob Resist Infect Control 2019; 8: 170.
2. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014; 15: 1351-70.
3. Loho T, Dharmayanti A. Colistin: an antibiotic and its role in multiresistant Gram-negative infections. Acta Med Indones 2015; 47: 157-68.
4. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
5. T amma PD, Newland JG, Pannaraj PS, et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J 2013; 32: 17-22.
6. Ecemiş S. Y oğun bakım ünitelerinde kolistin kan düzeyi izlemi ve değerlendirilmesi. Yüksek Lisans Tezi. Ankara, 2019
7. Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. Expert Opin Drug Saf 2015; 14: 1687-1701.
8. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53: 879-84.
9. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother. 2010; 54: 4503-5.
10. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.
11. Bulut C, Yamazhan T, Işıkgöz M, Pullukçu H, Ulusoy S.İlk Doz kolistin tedavisini takiben gelişen toksisite: Kolistin ne kadar güvenli? ANKEM Derg 2016; 30: 57-61.
12. Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis. Minn Med 1973; 56: 31-5.
13. Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 2006; 58: 1078-81.
14. Velkov T, Dai C, Ciccotosto GD, Cappai R, Hoyer D, Li J. Polymyxins for CNS infections: Pharmacology and neurotoxicity. Pharmacol Ther 2018; 181: 85-90.
15. Koch-W eser J, Sidel VW , Federman EB, Kanarek P , Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-68.
16. Reed MD, Stern RC, O’Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41: 645-654.
Volume 2, Issue 1, 2021
Page : 25-27
_Footer